Molbio Diagnostics Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹130(16.11%)
Premium (ELP)
Subscription for Molbio Diagnostics Limited's Initial Public Offering is currently underway, targeting total proceeds of 1,16,46,246 Shares. The offering composition includes 24,80,246 Shares in new capital infusion and ₹742.45 Cr in existing shareholder sales.
The active price band of ₹768 to ₹807 and minimum lot requirement of 18 shares define the current investment parameters. Market participants are actively evaluating this opportunity during the subscription window.
The application deadline is fast approaching on Aug 12, 2026. Following Subscription closure, allotment will be processed on Aug 13, 2026, leading to the anticipated listing on Aug 17, 2026 at the NSE, BSE exchange platform.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Founded in 2000, Molbio Diagnostics Limited is a healthcare company focused on providing fast, accurate, and affordable diagnostic solutions for both infectious and non-communicable diseases. Its key product, the Truenat platform, is a portable PCR-based testing system that can deliver results within an hour, even in remote or low-resource areas, and is used to detect diseases like tuberculosis, COVID-19, hepatitis, HIV, and HPV. The company also offers radiology, digital pathology, and breast health screening solutions through its group entities and partners. It operates five manufacturing facilities across India to produce diagnostic devices, test kits, and portable X-ray systems. With a presence in over 80 countries and a strong distributor network, Molbio serves public health programs, hospitals, and diagnostic labs worldwide, generating revenue from both device sales and recurring test kit usage. As of March 31, 2025, the company had around 1,000 permanent employees along with over 1,500 contract workers.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Innovative Diagnostic Technology: Company nu flagship molecular testing platform rapid ane accurate diagnosis aape che, je healthcare sector ma strong differentiation create kare che.
- Recurring Consumable Revenue: Devices install thaya pachhi test kits ni regular demand ave che, je company ne stable ane repeat income aape che.
- Strong Financial Growth: Recent years ma revenue ane profit ma fast growth joi male che, je business scalability ane demand darshave che.
- High Dependence on Government Orders: Revenue no moto hissa government ane institutional clients mathi ave che, je policy changes thi impact thai shake che.
- Product Concentration Risk: Company nu major revenue limited diagnostic tests (especially TB related) par dependent che, je diversification risk create kare che.
- Working Capital Intensive: Inventory ane operations maintain karva ma heavy working capital joiye, je cash flow par pressure muki shake che.
- Sriram Natarajan
- Dr. Chandrasekhar Bhaskaran Nair
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Exxora Trading LLP
Molbio Diagnostics Limited
Kfin Technologies Limited